|Hong Kong and Singapore - The Financial Times will host its inaugural FT Asia Pharma-Healthcare Summit at the Intercontinental in Singapore on 20 May, 2015. Thought leaders from across the healthcare supply chain will come together to share regional expertise on the changing healthcare needs of Asian populations and the commercial prospects for Asia’s healthcare industry.
Organised in partnership with Deloitte and associate sponsors IMS Health and Information Fulfillment Ltd., the summit will provide a forum for constructive dialogue on the challenges and opportunities facing the healthcare and life sciences industry as it expands in Asia Pacific.
The FT Asia Pharma-Healthcare Summit will be chaired by Financial Times pharmaceutical correspondent, Andrew Ward. The agenda will feature speakers from major pharmaceutical and biotechnology companies including AstraZeneca, Johnson & Johnson, Merck, Roche, Novartis, UCB, Baxter and Sanofi Pasteur.
Giles Platford, President of Emerging Markets at Takeda, will deliver the keynote address. His presentation will focus on challenges and opportunities for healthcare in Asia, including the impact of rising government investment and changes in the prevalence of certain diseases that affect businesses operating in the region.
Other speakers include:
Lisa Yeoh, Managing Director, Singapore and Brunei, Merck Sharp & Dohme
Joshi Venugopal, Managing Director, Singapore and Asian Emerging Markets, Novartis
Shankar Kaul, President and Region Head, Emerging Asia, Baxter Healthcare
Lance Little, Managing Director, Asia Pacific, Roche Diagnostics
Ajay Gautam, Executive Director and Head of Collaborations, AstraZeneca
Laurent Metz, Senior Director, HEMA and Clinical Research, Johnson & Johnson
Thomas Triomphe, Vice President, Head of Asia-Pacific, Sanofi Pasteur
Karen Eryou, Senior Director, Corporate Compliance APAC, UCB
Raman Singh, President, Emerging Markets, Mundipharma
Christian Hogg, Chief Executive Officer, Hutchison ChinaMediTech
The FT Asia Pharma-Healthcare Summit will feature a variety of panel discussions and presentations exploring the following topic areas:
The changing healthcare needs of populations in Asia: In a rapidly developing part of the world, what are the standout epidemiological trends in health? What are the biggest gaps in demand for treatment and how can businesses access the market? How can businesses work with communities to identify and meet changing healthcare needs? What are the economic benefits of different healthcare systems and how are different countries managing the transition from out-of-pocket to universal healthcare?
Commercial prospects for Asia’s healthcare and life sciences industry:Many global companies are setting up R&D activities in Asia to take advantage of the region’s growing talent pool. Asia’s home-grown healthcare industry is also growing rapidly, but challenges include rising labour costs and regulatory reform. So what are governments doing to help businesses and what do they expect in return? What are the new potential risks for firms looking to expand into Asian emerging markets?
Market access for the pharmaceutical industry in Asia: Regulation and standards for market access vary enormously throughout Asia, so how will proposed harmonisation schemes affect businesses, providers and patients? What can be done to get more innovative branded products into the market? What are the benefits and disadvantages of risk-sharing agreements? Is there potential for an EMA/FDA type body that covers the whole Asia-Pacific region and to what extent will the demands of regulators there align with those in the US or Europe?
Building and maintaining positive relationships with stakeholders:Standards for interaction between industry, payers, providers and patients need to be clearly defined and this is still an ongoing process in countries all over Asia. How can businesses appropriately communicate value to providers that operate in multiple markets with different payment structures and how should practitioners and patients be educated about conditions and treatment options?
For more information and to register for the FT Asia Pharma-Healthcare Summit, please visit: live.ft.com/asiapharma
For further information, please contact:
Communications Manager, Asia Pacific
T: +852 2905 5519
About the Financial Times Live:
Chaired by senior journalists from the Financial Times Group, the summits, conferences, awards and strategic forums organised by FT Live gather the world’s brightest minds and most influential decision-makers.
Exclusive on-stage interviews, stimulating presentations and lively panel debates – available on multiple content platforms – provide the cutting-edge insights, unique personalities and peer audience engagement that have the power to transform finance, business, politics, society and culture.
The Financial Times provides essential news, comment, data and analysis for the global business community. It has a combined paid print and digital circulation of 720,000. FT education products now serve two thirds of the world’s top 50 business schools.
About Life Sciences and Health Care at Deloitte*:
Deloitte’s life sciences and health care (LSHC) industry group is composed of more than 7,300 professionals in over 70 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.